Bibliography
Export 32 results:
Filters: Author is Trofe,J. [Clear All Filters]
Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int. 2006;19(4):295-302.
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant. 2005;5(2):356-65.
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant. 2005;5(4 Pt 1):775-80.
Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality. Transplant Proc. 2005;37(2):583-4.
Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005;37(2):956-7.
Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc. 2005;37(2):795-7.
Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: multivariate analysis of risk factors for acute rejection. Transplant Proc. 2005;37(2):798-9.
Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. Transplant Proc. 2005;37(2):817-8.
Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation. Transplant Proc. 2005;37(2):812-3.
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant. 2005;5(11):2740-4.
Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37(2):954-5.
A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc. 2005;37(2):802-3.
Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc. 2005;37(2):958-9.
Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum. 2004;47(11):1898-903.
Donor transmitted malignancies. Ann Transplant. 2004;9(1):53-6.
Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78(11):1676-82.
Posttransplant malignancy. Prog Transplant. 2004;14(3):193-200.
Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation. 2004;78(7):972-7.
Donors with central nervous system malignancies: are they truly safe? Transplantation. 2003;76(2):340-3.
The Israel Penn International Transplant Tumor Registry. AMIA Annu Symp Proc. 2003:1053.
De novo breast cancer in renal transplant recipients. Transplant Proc. 2002;34(5):1778-9.
De novo sarcomas in solid organ transplant recipients. Transplant Proc. 2002;34(5):1786-7.
Gastric cancer in transplant recipients: detection of malignancy [correction of malignacy] by aggressive endoscopy. Transplant Proc. 2002;34(5):1784-5.